Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
|Videos|April 30, 2021
Dr. Raj S. Pruthi discusses the short- and long-term consequences of burnout
Author(s)Urology Times staff
“Suicide is a disproportionate cause of mortality in physicians,” Pruthi says.
Advertisement
In part 3 of Urology Times’® interview with Raj S. Pruthi, MD, MHA, FACS, he discusses how burnout can have adverse effects on both health care providers as well as patients. Pruthi is professor and chair of urology, University of California, San Francisco.
Advertisement
Related to this article
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.
Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.
Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.
Advertisement
Advertisement
Trending on Urology Times
1
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
2
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
5